Drugs / IMM-101
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01308762 | Mar → Sep 2010 | melanoma | Immodulon Therapeutics Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03009058 | May → Aug 2017 | metastatic malignant neoplasm | Immodulon Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT01559818 | Feb 2012 → Jul 2019 | melanoma | Immodulon Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06498518 | Jun 2024 → May 2025 | malignant pancreatic neoplasm | Karen Carty | Withdrawn | No outcome recorded |
| Phase 2 | NCT05118724 | Dec 2021 → Apr 2027 expected | colorectal cancer | AIO-Studien-gGmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03711188 | Oct 2018 → Dec 2021 | melanoma | Immodulon Therapeutics Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01303172 | Jun 2011 → Jun 2014 | malignant pancreatic neoplasm | Immodulon Therapeutics Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04442048 | Oct 2020 → May 2024 | COVID-19, cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04137822 | — | malignant exocrine pancreas neoplasm | Impatients N.V. trading as myTomorrows | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137822 ↗ |
| Modality | Other / unclassified | “IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.” NCT01303172 ↗ |
| Route | Other | “A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks” NCT01303172 ↗ |